Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

GALANTAMINE SYNTHETIC FOR SYSTEM SUITABILITY CRS (5 MG)

GALANTAMINE SYNTHETIC FOR SYSTEM SUITABILITY CRS (5 MG)

04/04/1953

DISCOVER
HEPATITIS A VACCINE (INACTIVATED, NON ADSORBED) BRP (1 ML)

HEPATITIS A VACCINE (INACTIVATED, NON ADSORBED) BRP (1 ML)

ND

DISCOVER
CLAZURIL CRS (10 MG)

CLAZURIL CRS (10 MG)

101831-36-1

DISCOVER
RESVERATROL CRS (25 MG)

RESVERATROL CRS (25 MG)

501-36-0

DISCOVER
STRYCHNINE CRS (30 MG)

STRYCHNINE CRS (30 MG)

57-24-9

DISCOVER
BRUCINE CRS (30 MG)

BRUCINE CRS (30 MG)

357-57-3

DISCOVER
CETIRIZINE FOR PEAK IDENTIFICATION CRS (1.01 MG)

CETIRIZINE FOR PEAK IDENTIFICATION CRS (1.01 MG)

83881-52-1

DISCOVER
VARICELLA VACCINE (LIVE) BRP (420 MG)

VARICELLA VACCINE (LIVE) BRP (420 MG)

NA

DISCOVER
KUDZUVINE ROOT DRY EXTRACT HRS (200 MG)

KUDZUVINE ROOT DRY EXTRACT HRS (200 MG)

NA

DISCOVER
GALANTAMINE RACEMIC MIXTURE CRS (10 MG)

GALANTAMINE RACEMIC MIXTURE CRS (10 MG)

193146-85-9

DISCOVER
HESPERIDIN CRS (20 MG)

HESPERIDIN CRS (20 MG)

520-26-3

DISCOVER
OLEANOLIC ACID CRS (20 MG)

OLEANOLIC ACID CRS (20 MG)

508-02-1

DISCOVER